Pépinière - Paris Santé Cochin
29 rue du Faubourg Saint Jacques
About EyevensysEyevensys S.A.S is a privately held biotechnology company developing a game changing approach to express therapeutic proteins in situ for the treatment of major ophthalmic diseases.
Founder and CSO: Francine Behar-Cohen
CEO: Raffy Kazandjian
Please click here for clinical trial information.
13 articles with Eyevensys
Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases, announced the U.S. Food and Drug Administration has granted an orphan-drug designation for EYS611 for the treatment of retinitis pigmentosa.
3/13/2020Companies strengthen their leadership teams and executive boards with this week's Movers & Shakers.
Eyevensys announced the expansion of its leadership team with the appointment of Gerald Cagle as the Board’s Chairman, Francine Behar-Cohen to Chief Innovation Officer and Thierry Bordet as the Chief Scientific Officer.
Eyevensys Presents Initial Data from Phase I/II Trial of Innovative, Non-Viral Gene Therapy for Ocular Diseases at 11th Annual Ophthalmology Innovation Summit
Eyevensys a private, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases, this week presented results from part 1 of its phase I/II study for non-infectious uveitis (NIU) at the Ophthalmology Innovation Summit’s (OIS) 11th Annual OIS@AAO conference on October 10, 2019 in San Francisco
– Eyevensys, a clinical stage biotech company developing non-viral gene therapies for ophthalmic diseases, today announced that Gerald (Jerry) Cagle, Ph.D., former Senior Vice President and Chief Scientific Officer at Alcon Laboratories has joined its Board of Directors.
Dr. Zilliox, who joined the Eyevensys board in May 2016, has more than 25 years of global clinical development expertise.
Eyevensys Announces The First-In-Human Treatment With Its GroundBreaking EyeCET ElectroTransfection Technology For Eye Diseases
Eyevensys Receives Approval From The UK Medicines And Healthcare Products Regulatory Agency To Advance its EyeCET Platform Into Clinical Development
Eyevensys Receives Approval From The French Product Security Regulatory Agency ANSM To Advance Its Eyecet Platform Into Clinical Development
Eyevensys Appoints Leading Life Sciences Executive And Ophthalmology Expert Dr. Garth Cumberlidge As Chairman